DOW JONES27,588.62-372.18 -1.33%
S&P 5003,181.71-44.18 -1.37%
NASDAQ9,126.89-94.39 -1.02%

Canaccord Genuity Maintains Buy on Castle Biosciences, Raises Price Target to $35

Canaccord Genuity analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $34 to $35.

Benzinga · 12/27/2019 15:09

Canaccord Genuity analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $34 to $35.